Haart Tolerability: Post-Exposure Prophylaxis in Healthcare Workers versus Treatment in HIV-Infected PatientsTiziana Quirino, Fosca Niero, Elena Ricci et al.|Antiviral Therapy|2000Cited by 30
Are direct-acting antivirals safe and effective in hepatitis C virus-cryoglobulinemia? virological, immunological, and clinical data from a real-life experienceMatteo Passerini, Giuliano Rizzardini, Alessandro Luciano Croci et al.|European Journal of Gastroenterology & Hepatology|2018Cited by 24
A Boceprevir Failure in a Patient Infected with HCV Genotype 1G: Importance and Limitations of Virus Genotyping Prior to HCV Protease-Inhibitor-Based TherapyValeria Cento, Francesca Ceccherini‐Silberstein, Simona Landonio et al.|Antiviral Therapy|2013Cited by 19
Strategic use of dual regimens of boosted protease inhibitors plus maraviroc in poorly adherent subjects in view of long-acting drugsAmedeo Capetti, Giuliano Rizzardini, Mariangela Micale et al.|Medicine|2017Cited by 3
Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and RibavirinaMarta Gentili, Sonia Radice, C. Magni et al.|The Breast Journal|2016Cited by 3